Intrinsic ICAM-1/LFA-1 activation mediates altered responsiveness of atopic asthmatic airway smooth muscle

• Published in: American journal of physiology. Lung cellular and molecular physiology 2000-06, Vol.278 (6), p.1154-L1163
• Main Authors: Grunstein, Michael M, Hakonarson, Hakon, Maskeri, Neil, Kim, Cecilia, Chuang, Sing
• Format: Article
• Language: English
• Subjects: Animals; Asthma - blood; Asthma - etiology; Asthma - immunology; Asthma - physiopathology; Cells, Cultured; Gene Expression; Gene Expression Regulation - physiology; Humans; Hypersensitivity - complications; Immunization; In Vitro Techniques; Intercellular Adhesion Molecule-1 - genetics; Intercellular Adhesion Molecule-1 - physiology; Interleukin-5 - physiology; Lymphocyte Function-Associated Antigen-1 - genetics; Lymphocyte Function-Associated Antigen-1 - physiology; Muscle, Smooth - immunology; Muscle, Smooth - physiopathology; Rabbits; Trachea - immunology; Trachea - physiopathology
• ISSN: 1040-0605; 1522-1504
• DOI: 10.1152/ajplung.2000.278.6.L1154

Division of Pulmonary Medicine, Joseph Stokes, Jr. Research Institute, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 Cell adhesion molecules (CAMs) have been importantly implicated in the pathobiology of the airway responses in allergic asthma, including inflammatory cell recruitment into the lungs and altered bronchial responsiveness. To elucidate the mechanism of CAM-related mediation of altered airway responsiveness in the atopic asthmatic state, the expressions and actions of intercellular adhesion molecule-1 (ICAM-1) and its counterreceptor ligand lymphocyte function-associated antigen-1 (LFA-1; i.e., CD11a/CD18) were examined in isolated rabbit airway smooth muscle (ASM) tissues and cultured human ASM cells passively sensitized with sera from atopic asthmatic patients or nonatopic nonasthmatic (control) subjects. Relative to control tissues, the atopic asthmatic sensitized ASM exhibited significantly enhanced maximal contractility to acetylcholine and attenuated relaxation responses to isoproterenol. These proasthmatic changes in agonist responsiveness were ablated by pretreating the atopic sensitized tissues with a monoclonal blocking antibody (MAb) to either ICAM-1 or CD11a, whereas a MAb directed against the related 2 -integrin Mac-1 had no effect. Moreover, relative to control tissues, atopic asthmatic sensitized ASM cells displayed an autologously upregulated mRNA and cell surface expression of ICAM-1, whereas constitutive expression of CD11a was unaltered. Extended studies further demonstrated that 1 ) the enhanced expression and release of soluble ICAM-1 by atopic sensitized ASM cells was prevented when cells were pretreated with an interleukin (IL)-5-receptor- blocking antibody and 2 ) administration of exogenous IL-5 to naive (nonsensitized) ASM cells induced a pronounced soluble ICAM-1 release from the cells. Collectively, these observations provide new evidence demonstrating that activation of the CAM counterreceptor ligands ICAM-1 and LFA-1, both of which are endogenously expressed in ASM cells, elicits autologously upregulated IL-5 release and associated changes in ICAM-1 expression and agonist responsiveness in atopic asthmatic sensitized ASM. asthma; interleukin-5; cholinergic contraction; -adrenergic stimulation; intercellular adhesion molecule-1; lymphocyte function-associated antigen-1